Skip to content

Research at St Andrews

Defining dormancy in mycobacterial disease

Research output: Contribution to journalArticle

Abstract

Tuberculosis remains a threat to global health and recent attempts to shorten therapy have not succeeded mainly due to cases of clinical relapse. This has focussed attention on the importance of “dormancy” in tuberculosis. There are a number of different definitions of the term and a similar multiplicity of different in vitro and in vivo models. The danger with this is the implicit assumption of equivalence between the terms and models, which will make even more difficult to unravel this complex conundrum. In this review we summarise the main models and definitions and their impact on susceptibility of Mycobacterium tuberculosis. We also suggest a potential nomenclature for debate. Dormancy researchers agree that factors underpinning this phenomenon are complex and nuanced. If we are to make progress we must agree the terms to be used and be consistent in using them.
Close

Details

Original languageEnglish
Pages (from-to)131-142
Number of pages12
JournalTuberculosis
Volume99
Early online date28 May 2016
DOIs
Publication statusPublished - Jul 2016

    Research areas

  • Mycobacterium tuberculosis, Dormancy, Latency, Persistence, Mycobacteria

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform

    Baron, V. O., Chen, M., Hammarstrom, B., Hammond, R. J. H., Glynne-Jones, P., Gillespie, S. H. & Dholakia, K., 14 May 2020, In : Communications Biology. 3, 8 p., 236.

    Research output: Contribution to journalArticle

  2. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., Dec 2019, In : Journal of Antimicrobial Chemotherapy. 74, 12, p. 3530–3536 7 p.

    Research output: Contribution to journalArticle

  3. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  4. Sample detection device

    Hammond, R. J. H. & Gillespie, S. H., 12 Sep 2019, Patent No. US 2019 / 0277759 A1, Priority date 18 Nov 2016, Priority No. GBGB1619509.1A

    Research output: Patent

Related by journal

  1. The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay

    Rachow, A., Saathoff, E., Mtafya, B., Mapamba, D., Mangu, C., Rojas-Ponce, G., Ntinginya, N. E., Boeree, M., Heinrich, N., Gillespie, S. H., Hoelscher, M. & PanACEA Consortium, 4 Apr 2018, In : Tuberculosis. In press

    Research output: Contribution to journalArticle

  2. Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB

    Barr, D. A., Kamdolozi, M., Nishihara, Y., Ndhlovu, V., Khonga, M., Davies, G. R. & Sloan, D. J., May 2016, In : Tuberculosis. 98, p. 110-115 6 p.

    Research output: Contribution to journalArticle

  3. HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model - A potential novel therapeutic target

    Hu, Y., Liu, A., Menendez, M. C., Garcia, M. J., Oravcova, K., Gillespie, S. H., Davies, G. R., Mitchison, D. A. & Coates, A. R. M., Jan 2015, In : Tuberculosis. 95, 1, p. 31-36 6 p.

    Research output: Contribution to journalArticle

ID: 243086204

Top